| answer text |
<p>The National Institute for Care and Excellence (NICE) published a recommendation
in March 2023 that people with type 2 diabetes, who have multiple daily insulin injections
and a condition or disability that means they cannot use capillary blood glucose monitoring,
should be offered Continuous Glucose Monitoring (CGM) technology, either real time
or intermittent, to support self-monitoring.</p><p> </p><p>The NICE also recommended
in March 2023 that adults with insulin-treated type 2 diabetes having their blood
glucose monitored by a care worker or healthcare professional, are offered CGM. The
rationale is that CGM can help to improve glycaemic control in adults with type 2
diabetes who use insulin.</p>
|
 |
